The Express Tribune |
Glaxo Asthma Drug Stumbles in Ambitious Heart Patient Study
Bloomberg GlaxoSmithKline Plc's Breo Ellipta medicine didn't extend lives in an ambitious study that sought to show the drug could help patients suffering from both lung and heart troubles. Patients taking the inhaled asthma drug Breo were 12 percent less likely … GSK inhaler trial fails to show longer life Respiratory drug trial failure deals blow to GSK revival plan GSK and Theravance Announce Results From the SUMMIT COPD CV Survival Study |
View full post on asthma – Google News